ZURA
Zura Bio Ltd - Ordinary Shares - Class A

1,077
Mkt Cap
$251.64M
Volume
269,980.00
52W High
$4.68
52W Low
$0.97
PE Ratio
-5.47
ZURA Fundamentals
Price
$3.67
Prev Close
$3.87
Open
$3.87
50D MA
$3.40
Beta
1.09
Avg. Volume
1.11M
EPS (Annual)
-$0.6046
P/B
2.32
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Alberta Investment Management Corp Buys Shares of 133,200 Zura Bio Limited $ZURA
Alberta Investment Management Corp bought a new position in Zura Bio Limited (NASDAQ:ZURA - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Chardan Capital Reiterates Buy Rating for Zura Bio (NASDAQ:ZURA)
Chardan Capital reissued a "buy" rating and issued a $10.00 price target on shares of Zura Bio in a report on Friday...
MarketBeat·4d ago
News Placeholder
Zura Bio Limited (NASDAQ:ZURA) Given Average Rating of "Moderate Buy" by Brokerages
Zura Bio Limited (NASDAQ:ZURA - Get Free Report) has been given an average rating of "Moderate Buy" by the six ratings firms that are presently covering the stock, Marketbeat.com reports. One analyst...
MarketBeat·5d ago
News Placeholder
Wall Street Zen Downgrades Zura Bio (NASDAQ:ZURA) to Sell
Wall Street Zen lowered shares of Zura Bio from a "hold" rating to a "sell" rating in a research report on Sunday...
MarketBeat·5d ago
News Placeholder
Zura Bio (NASDAQ:ZURA) Issues Earnings Results
Zura Bio (NASDAQ:ZURA - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.02...
MarketBeat·6d ago
News Placeholder
Zura Bio Reports Third Quarter 2025 Financial Results and Recent Corporate Updates
Zura Bio Limited (Nasdaq: ZURA) (Zura Bio or the Company), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today...
Business Wire·7d ago
News Placeholder
Zura Bio (NASDAQ:ZURA) Rating Increased to Hold at Wall Street Zen
Wall Street Zen upgraded shares of Zura Bio from a "sell" rating to a "hold" rating in a research report on Saturday...
MarketBeat·11d ago
News Placeholder
Novartis Drug Shows Improvement In Sjögren's Disease In Late-Stage Trials: Analyst Deems Data Positive For Zura Bio As Well
Novartis now sees the potential for the drug to become the first and only targeted treatment approved for patients with the disease.
Stocktwits·3mo ago
News Placeholder
Zura Bio to Present at the Leerink Partners Global Healthcare Conference
Zura Bio Limited (Nasdaq: ZURA) (Zura Bio), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that...
Business Wire·9mo ago
News Placeholder
Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis
Zura Bio Limited (Nasdaq: ZURA) (Zura Bio), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced the...
Business Wire·11mo ago

Latest ZURA News

View

Advertisement|Remove ads.

Advertisement|Remove ads.